Julie H Harreld1, Emily M Bratton2, Sara M Federico3, Xingyu Li4, William Grover5, Yimei Li4, Natalie C Kerr6,7,8, Matthew W Wilson6,8,9, Mary E Hoehn6,7,8. 1. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Texas Oculoplastic Consultants, Austin, Texas. 3. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Ophthalmology, Medstar Georgetown University Hospital, Washington, District of Columbia. 6. Department of Ophthalmology, University of TN Hamilton Eye Institute, Memphis, Tennessee. 7. Department of Pediatrics, University of TN College of Medicine, Memphis, Tennessee. 8. Department of Surgery, Division of Ophthalmology, St. Jude Children's Research Hospital, Memphis, Tennessee. 9. Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: Approximately 30% of patients with metastatic (stage M) neuroblastoma present with periorbital ecchymosis from orbital osseous disease. Though locoregional disease is staged by imaging, the prognostic significance of metastatic site in stage M disease is unknown. We hypothesize that, compared to nonorbital metastasis, orbital metastasis is associated with decreased survival in patients with stage M neuroblastoma, and that periorbital ecchymosis reflects location and extent of orbital disease. PROCEDURE: Medical records and imaging from 222 patients with stage M neuroblastoma seen at St. Jude Children's Research Hospital between January 1995 and May 2009 were reviewed. Thirty-seven patients were <18 months of age at diagnosis and 185 were ≥18 months of age. Overall survival (OS) and 5-year survival (5YS) were compared for patients with and without orbital, calvarial and nonorbital osseous metastasis, and with and without periorbital ecchymosis (log-rank test). Associations of periorbital ecchymosis with orbital metastasis location/extent were explored (Fisher's exact test, t-test). RESULTS: In patients ≥18 months of age, only orbital metastasis was associated with decreased 5YS (P = 0.0323) and OS (P = 0.0288). In patients <18 months of age, neither orbital, calvarial, or nonorbital bone metastasis was associated with OS or 5YS. Periorbital ecchymosis was associated with higher number of involved orbital bones (P = 0.0135), but not location or survival. CONCLUSIONS: In patients ≥ 18 months of age with stage M neuroblastoma, orbital metastatic disease is associated with decreased 5YS and OS. In future clinical trials, orbital disease may be useful as an imaging-based risk factor for substratification of stage M neuroblastoma.
BACKGROUND: Approximately 30% of patients with metastatic (stage M) neuroblastoma present with periorbital ecchymosis from orbital osseous disease. Though locoregional disease is staged by imaging, the prognostic significance of metastatic site in stage M disease is unknown. We hypothesize that, compared to nonorbital metastasis, orbital metastasis is associated with decreased survival in patients with stage M neuroblastoma, and that periorbital ecchymosis reflects location and extent of orbital disease. PROCEDURE: Medical records and imaging from 222 patients with stage M neuroblastoma seen at St. Jude Children's Research Hospital between January 1995 and May 2009 were reviewed. Thirty-seven patients were <18 months of age at diagnosis and 185 were ≥18 months of age. Overall survival (OS) and 5-year survival (5YS) were compared for patients with and without orbital, calvarial and nonorbital osseous metastasis, and with and without periorbital ecchymosis (log-rank test). Associations of periorbital ecchymosis with orbital metastasis location/extent were explored (Fisher's exact test, t-test). RESULTS: In patients ≥18 months of age, only orbital metastasis was associated with decreased 5YS (P = 0.0323) and OS (P = 0.0288). In patients <18 months of age, neither orbital, calvarial, or nonorbital bone metastasis was associated with OS or 5YS. Periorbital ecchymosis was associated with higher number of involved orbital bones (P = 0.0135), but not location or survival. CONCLUSIONS: In patients ≥ 18 months of age with stage M neuroblastoma, orbital metastatic disease is associated with decreased 5YS and OS. In future clinical trials, orbital disease may be useful as an imaging-based risk factor for substratification of stage M neuroblastoma.
Authors: Rani E George; Shuli Li; Cheryl Medeiros-Nancarrow; Donna Neuberg; Karen Marcus; Robert C Shamberger; Michael Pulsipher; Stephan A Grupp; Lisa Diller Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: S G DuBois; Y Kalika; J N Lukens; G M Brodeur; R C Seeger; J B Atkinson; G M Haase; C T Black; C Perez; H Shimada; R Gerbing; D O Stram; K K Matthay Journal: J Pediatr Hematol Oncol Date: 1999 May-Jun Impact factor: 1.289
Authors: Veronica Moroz; David Machin; Andreas Faldum; Barbara Hero; Tomoko Iehara; Veronique Mosseri; Ruth Ladenstein; Bruno De Bernardi; Hervé Rubie; Frank Berthold; Katherine K Matthay; Tom Monclair; Peter F Ambros; Andrew D J Pearson; Susan L Cohn; Wendy B London Journal: Eur J Cancer Date: 2010-11-26 Impact factor: 9.162
Authors: Daniel A Morgenstern; Wendy B London; Derek Stephens; Samuel L Volchenboum; Barbara Hero; Andrea Di Cataldo; Akira Nakagawara; Hiroyuki Shimada; Peter F Ambros; Katherine K Matthay; Susan L Cohn; Andrew D J Pearson; Meredith S Irwin Journal: J Clin Oncol Date: 2014-03-24 Impact factor: 44.544
Authors: Gitta Bleeker; Berthe L van Eck-Smit; Koos H Zwinderman; Rogier Versteeg; Max M van Noesel; Boen L Kam; Gertjan J Kaspers; Annelies van Schie; Susan G Kreissman; Gregory Yanik; Barbara Hero; Matthias Schmidt; Geneviève Laureys; Bieke Lambert; Ingrid Øra; Johannes H Schulte; Huib N Caron; Godelieve A Tytgat Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-30 Impact factor: 9.236
Authors: Ting Tao; Hui Shi; Luca Mariani; Brian J Abraham; Adam D Durbin; Mark W Zimmerman; John T Powers; Pavlos Missios; Kenneth N Ross; Antonio R Perez-Atayde; Martha L Bulyk; Richard A Young; George Q Daley; A Thomas Look Journal: Proc Natl Acad Sci U S A Date: 2020-06-29 Impact factor: 11.205